A recent study published in the prestigious scientific journal The Lancet Psychiatry , with the participation of Dr. Lúcio Silva, a member of the clinical staff of The Clinic of Change, addresses issues that could revolutionize future approaches in the area of mental health.
A recent study, published in The Lancet Psychiatry and co-authored by Dr. Lúcio Silva, a member of the clinical staff at The Clinic of Change, located in Lisbon, highlights a critical issue: the insufficient description of the psychotherapeutic techniques used in these approaches with drugs such as Psilocybin and MDMA compromises the replicability and interpretation of the results.
In recent years, psychedelics have re-emerged as promising tools in therapeutic contexts, providing an innovative approach to exploring the mind and consciousness, particularly in the treatment of conditions such as Resistant Depression, Generalized Anxiety Disorder or Post-Traumatic Stress Disorder (PTSD).
The research reveals that while psychedelics such as Psilocybin and MDMA are often studied for their pharmacological effects, little is known about the specific psychotherapeutic approaches that accompany them.
"There is a gap in the scientific literature that urgently needs to be filled to ensure that therapeutic advances can be replicated and applied across the board," says Dr. Lúcio Silva.
The clinical staff at The Clinic of Change, a pioneer in Portugal in the use of innovative therapeutic interventions, has been researching these approaches to Psychedelic-Assisted Psychotherapy, using the drug ketamine. This drug, often associated with the treatment of PTSD, is one of the few psychedelics whose use is accompanied by more detailed descriptions of therapeutic methodologies.
However, for other compounds, such as psilocybin, this documentation remains scarce.
The authors of the study point out that the lack of details about psychotherapeutic techniques - from the structure of the sessions to the strategies used to guide patients during psychedelic experiences - compromises not only the interpretation of the results, but also the safety and effectiveness of the interventions. For Dr. Lúcio Silva, it is "essential to standardize and document these techniques so that they can be shared and adapted in different clinical contexts".
The call from the researchers is clear: future studies should place as much emphasis on psychotherapeutic approaches as on the pharmacological aspects of psychedelics. This methodological rigor will allow these innovative therapies to be integrated ever more safely and effectively into the treatment of mental illness, benefiting a growing number of patients seeking solutions to conditions that are often resistant to conventional treatments.
Read the full article here.
